Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedaSorb makes senior management changes, names new interim CEO
The company has also announced that Al Kraus has been elected to chairman of the board. William Miller has stepped down as chairman after two years of service.
The company has also announced that Al Kraus has been elected to chairman of the board. William Miller has stepped down as chairman after two years of service.
The collaboration is focused on identifying biomarkers in the field of systemic lupus erythematosus for clinical diagnostic purposes associated with the clinical development of Orencia, a Bristol-Myers Squibb
Mr McCormick succeeds Patrick Spangler, who has resigned as senior vice president and CFO, effective January 19, 2009. Most recently, Mr McCormick served as vice president of corporate
CPP-109 is Catalyst’s tablet formulation of vigabatrin being developed as a treatment for cocaine and methamphetamine addiction, as well as other addictions and obsessive-compulsive disorders. The randomized, double-blind,
Dr Caudrelier joined Theratechnologies in August 2007 and worked actively in the completion of the Phase III clinical program evaluating tesamorelin in HIV-associated lipodystrophy. Dr Caudrelier’s responsibilities will
Abbott’s 2009 outlook includes the acquisition of Advanced Medical Optics (AMO) as announced today (see separate news release). Abbott expects the AMO transaction to be neutral to ongoing
The single-dose, open-label study is designed to assess the pharmacokinetics, safety and tolerability of a gluteal injection of this risperidone formulation in approximately 26 patients diagnosed with chronic,
Mr Boisjoli most recently served as CFO and co-founder of Xanthus Pharmaceuticals, a Boston-based biotechnology company, where he was responsible for all financial business and operations and was
The FDA had requested that the data in a single study be reformatted. In addition, GSK conducted a review of other clinical studies taking this input into account.
Zingo powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age.